HGH Frag (176-191)

HGH Frag (176-191) is supplied by PEPTIDE.Power as a synthetic laboratory research reference material intended strictly for in-vitro and laboratory research use only. Corresponding to residues 176-191 of the human growth hormone sequence, this 16-amino-acid C-terminal fragment is offered as a lyophilized white to off-white powder produced by solid-phase peptide synthesis and purified to not less than 98% by reversed-phase HPLC, with identity and purity documented on the lot-specific Certificate of Analysis available on request.

The verified analytical identifiers for HGH Frag (176-191) are CAS Number 221231-10-3, molecular formula C78H123N23O23S2, and a monoisotopic-consistent average molecular weight of approximately 1,817 g/mol. The elemental composition (78 carbons, 123 hydrogens, 23 nitrogens, 23 oxygens, and 2 sulfur atoms) reflects the presence of methionine and cysteine-class contributions to the sulfur count, and provides a useful cross-check when confirming lot identity by mass spectrometry (ESI-MS or MALDI-TOF) against the theoretical [M+H]+ envelope. A partial 3-letter sequence tag (Phe-Arg-Ala-Gly-Met-Glu-Asn-Thr) is provided as an analytical reference alignment; residue count is 8 in that tag, within the full 16-amino-acid 176-191 hGH fragment cataloged under SKU HGH-Frag.

For analytical characterization, HGH Frag (176-191) is typically evaluated by orthogonal methods: reversed-phase HPLC (C18, TFA- or formic-acid modified acetonitrile/water gradients) for chromatographic purity, high-resolution mass spectrometry for molecular weight confirmation, and, where appropriate, amino-acid analysis or Edman/UPLC-MS peptide mapping for sequence verification. Residual solvent, water content (Karl Fischer), and counter-ion or acetate content may also be reported per lot. The lyophilized physical form supports extended storage stability when kept sealed, desiccated, and protected from light at recommended low-temperature conditions; reconstitution behavior in common laboratory diluents is typically assessed empirically by researchers as part of assay development.

Published scientific literature has examined HGH Frag (176-191) in preclinical and in-vitro research contexts, and it is frequently used as a comparator or reference standard in peptide analytical workflows. PEPTIDE.Power makes no therapeutic, diagnostic, or efficacy claims regarding this material and provides no administration or dosing guidance. HGH Frag (176-191) is not a drug, dietary supplement, cosmetic, or food, and is not intended for human or veterinary use, injection, or ingestion. All handling should follow standard laboratory practice for synthetic research peptides, with reference to the Certificate of Analysis and Safety Data Sheet.

Supplied as a lyophilized (freeze-dried) powder in a sealed vial. A research reference material - not a finished product and not a delivery device. Net contents per unit are shown in the product options.

Store the sealed lyophilized powder at -20 C, protected from light and moisture. After reconstitution for laboratory use, keep cold and use promptly. Handle per standard laboratory practice; a Safety Data Sheet (SDS) is available on request.

This material is sold to qualified laboratory and research buyers for lawful research use only. It is not a drug, supplement, cosmetic, or food, and is not for human or veterinary use, injection, or ingestion. By purchasing, you confirm you are 21 or older and will use this material only for lawful laboratory research.